Recent Updates
Recently added Catalysts
LAB Positive Sentiment

Standard BioTools Announces Conference Call and Webcast for First Quarter 2024 Financial Results on May 8, 2024

Key Takeaway: Standard BioTools Inc. has scheduled a conference call and webcast for May 8, 2024, to discuss its first quarter financial results for 2024. The management will go over these results and offer insights into the company's operational progress after the market closes. Interested individuals can join the call through specified phone numbers, and a live audio webcast will also be available online.
Price reaction · baseline $2.42 (2024-04-24 close) · hit after-hours · clean, no other LAB news in the window
day 0 close · peak
-2.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Standard BioTools will report first quarter 2024 financial results soon.
  • The conference call offers an opportunity for stakeholders to gain insights into operational progress.
  • The company's advancements in standardized technologies may lead to significant breakthroughs in human health.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced that it will report first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the market.
The Company’s management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on May 8, 2024, to discuss first quarter 2024 financial results and operational progress. A press release including the financial results will be publicly distributed before the call.
Individuals interested in listening to the conference call may do so by dialing:
US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297
Live audio of the webcast will be available online on the Investor Relations page of the Company’s website at Events & Presentations. The webcast will be archived and available on Standard BioTools™ Investor Relations page at investors.standardbio.com.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.
For Research Use Only. Not for use in diagnostic procedures.

Frequently Asked Questions

When will Standard BioTools report Q1 2024 results?

Standard BioTools will report its Q1 2024 financial results on May 8, 2024.

What time is the Standard BioTools conference call?

The conference call is scheduled for 1:30 p.m. PT on May 8, 2024.

How can I access the Standard BioTools conference call?

Callers can dial (888) 346-3970 in the US or (412) 902-4297 internationally.

Where can I find the webcast of the conference call?

The live webcast will be available on the Investor Relations page of the company’s website.

What technologies does Standard BioTools provide?

Standard BioTools offers mass cytometry and microfluidics technologies for biomedical research.

Last updated: Apr 25, 2024